Zydus Lifesciences gets FDA green light for acne treatment gel


Zydus Lifesciences Limited has secured final approval from the United States Food and Drug Administration (USFDA) for its Clindamycin Phosphate Gel USP, 1%. With annual sales of the acne treatment gel standing at a staggering USD 37 million in the U.S. (as of IQVIA MAT July 2023), the pharmaceutical giant is poised for significant market impact.

A Groundbreaking Solution for Acne Sufferers

This Clindamycin Phosphate Gel USP, 1% is engineered to treat acne effectively by decreasing the number of acne lesions. The gel utilizes Clindamycin, an antibiotic renowned for inhibiting bacterial growth. Zydus Lifesciences will produce the acne-fighting gel at its state-of-the-art topical manufacturing facility located in Changodar, Ahmedabad, India.

See also  Electric aircraft start-up Archer to go public via $3.8bn merger with Atlas Crest

A Long Line of Success for Zydus Lifesciences

With this recent approval, Zydus Lifesciences marks a pivotal milestone in its journey. The company now boasts an impressive total of 381 USFDA approvals. Furthermore, Zydus has filed over 444 Abbreviated New Drug Applications (ANDAs) since the beginning of the filing process in the fiscal year 2003-04.

See also  Walmart to acquire robotic e-grocery fulfillment company Alert Innovation

From India to the United States: The Global Reach of Zydus Lifesciences

The U.S. market entry of Zydus Lifesciences’ Clindamycin Phosphate Gel signifies the global reach of this Indian-based pharmaceutical company. With its latest approval from the USFDA for the acne treatment gel, the firm reaffirms its commitment to high-quality healthcare solutions worldwide.

See also  ESpace Networks closes $10m Series A round, strengthens leadership with key appointments

Anticipation is high as consumers await the rollout of Zydus Lifesciences’ Clindamycin Phosphate Gel USP, 1% in the U.S. market. Keep your eyes peeled for this revolutionary acne treatment.

Share This


Wordpress (0)